Display options
Cite
Kissmeyer A, Mathiasen IS, Latini S, et al. Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine. 1995;3(4):263-6doi: 10.1007/BF03021403.
Kissmeyer, A., Mathiasen, I. S., Latini, S., & Binderup, L. (1995). Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine, 3(4), 263-6. https://doi.org/10.1007/BF03021403
Kissmeyer, A, et al. "Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP)." Endocrine vol. 3,4 (1995): 263-6. doi: https://doi.org/10.1007/BF03021403
Kissmeyer A, Mathiasen IS, Latini S, Binderup L. Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine. 1995 Apr;3(4):263-6. doi: 10.1007/BF03021403. PMID: 21153172.
Copy Download .nbib Format: NLM
Share it on

Endocrine. 1995 Apr;3(4):263-6. doi: 10.1007/BF03021403.

Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP).

Endocrine

A Kissmeyer, I S Mathiasen, S Latini, L Binderup

Affiliations

  1. Department of Pharmacokinetics and Metabolism, Leo Pharmaceutical Products, DK-2750, Ballerup, Denmark.

PMID: 21153172 DOI: 10.1007/BF03021403

Abstract

Vitamin D(3), 25-hydroxyvitamin D(3) (25OHD(3)) and 1α,25-dihydroxyvitamin D(3) (1α,25(OH)(2)D(3)) bind to the vitamin D binding protein (DBP) in the serum. During the development of synthetic vitamin D analogues, it has been shown that the majority of analogues bind to DBP with a low affinity. This modifies their biological activitiesin vitro compared to 1α,25(OH)(2)D(3), since binding to DBP decreases the cellular uptake and access to the vitamin D receptor. It is therefore important to elucidate the possible role played by the binding or lack of binding to DBPin vivo. We have investigated the relationship between the binding affinity for human DBP and the serum level and serum half-life (t(1/2)) in rats of a series of new vitamin D analogues. The binding affinity for DBP was determined by displacement of(3)H-1,25(OH)(2)D(3) from DBP attached to Affi-Gel 10. The serum levels in rats following a single intravenous dose were assessed by HPLC and the serum half-life was determined for each analogue. In the group of vitamin D analogues which showed a low or no affinity for DBP, we have identified compounds with a short t(1/2) and compounds with a long t(1/2), all characterized by low initial serum levels. Compounds with a long t(1/2) were also found in the group with a high affinity for DBP, and they were easily identifiable by their high initial serum level. These results showed that the initial serum level of vitamin D analogues correlated with the affinity for DBP, but that there seemed to be no correlation with the metabolic rate as reflected by measurement of the serum half-life of the analogues.

References

  1. J Bone Miner Res. 1994 Aug;9(8):1277-88 - PubMed
  2. Biochem Pharmacol. 1991 Jun 1;41(11):1601-6 - PubMed
  3. Biochem Pharmacol. 1988 Mar 1;37(5):889-95 - PubMed
  4. Endocrinology. 1991 Apr;128(4):1687-92 - PubMed
  5. Biochem Pharmacol. 1994 Mar 15;47(6):987-93 - PubMed
  6. N Engl J Med. 1989 Apr 13;320(15):980-91 - PubMed
  7. Exp Clin Immunogenet. 1992;9(3):161-75 - PubMed
  8. J Bone Miner Res. 1991 Oct;6(10):1051-7 - PubMed
  9. J Steroid Biochem. 1988 Apr;29(4):381-6 - PubMed
  10. Biochem Pharmacol. 1991 Sep 27;42(8):1569-75 - PubMed
  11. J Biol Chem. 1976 Aug 25;251(16):4803-9 - PubMed
  12. J Clin Invest. 1981 Mar;67(3):589-96 - PubMed
  13. J Steroid Biochem Mol Biol. 1992 Sep;42(8):855-61 - PubMed

Publication Types